Charles Schwab Investment Management Inc. Acquires 249,412 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Charles Schwab Investment Management Inc. raised its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 11.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,401,533 shares of the biotechnology company’s stock after acquiring an additional 249,412 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.03% of ADMA Biologics worth $48,007,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Quest Partners LLC acquired a new position in ADMA Biologics in the 2nd quarter worth about $29,000. Hollencrest Capital Management acquired a new position in ADMA Biologics in the 3rd quarter valued at approximately $30,000. CWM LLC lifted its holdings in ADMA Biologics by 114.2% during the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after buying an additional 4,367 shares during the period. Acadian Asset Management LLC acquired a new position in shares of ADMA Biologics in the 2nd quarter worth approximately $93,000. Finally, USA Financial Formulas grew its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares during the period. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on ADMA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Finally, HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th.

ADMA Biologics Stock Performance

ADMA Biologics stock opened at $20.11 on Monday. The company has a market capitalization of $4.75 billion, a PE ratio of 71.82 and a beta of 0.64. ADMA Biologics, Inc. has a twelve month low of $3.60 and a twelve month high of $23.64. The firm has a fifty day simple moving average of $19.08 and a two-hundred day simple moving average of $15.40. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The company had revenue of $119.84 million during the quarter, compared to the consensus estimate of $107.25 million. During the same quarter in the prior year, the company earned $0.01 earnings per share. Research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now directly owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.